WallStSmart

AstraZeneca PLC (AZN)vsInteger Holdings Corp (ITGR)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AstraZeneca PLC generates 3207% more annual revenue ($61.37B vs $1.86B). AZN leads profitability with a 17.0% profit margin vs 7.6%. AZN appears more attractively valued with a PEG of 1.47. AZN earns a higher WallStSmart Score of 60/100 (C+).

AZN

Buy

60

out of 100

Grade: C+

Growth: 5.3Profit: 8.0Value: 6.7Quality: 5.0
Piotroski: 6/9Altman Z: 1.48

ITGR

Buy

51

out of 100

Grade: C-

Growth: 7.3Profit: 5.5Value: 4.0Quality: 6.5
Piotroski: 3/9Altman Z: 1.93
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AZNUndervalued (+19.3%)

Margin of Safety

+19.3%

Fair Value

$196.68

Current Price

$158.75

$37.93 discount

UndervaluedFair: $196.68Overvalued
ITGRUndervalued (+7.8%)

Margin of Safety

+7.8%

Fair Value

$94.60

Current Price

$125.08

$30.48 discount

UndervaluedFair: $94.60Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AZN4 strengths · Avg: 8.8/10
Market CapQuality
$263.09B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
20.8%9/10

Every $100 of equity generates 21 in profit

Operating MarginProfitability
23.5%8/10

Strong operational efficiency at 23.5%

Free Cash FlowQuality
$2.13B8/10

Generating 2.1B in free cash flow

ITGR2 strengths · Avg: 9.0/10
EPS GrowthGrowth
52.9%10/10

Earnings expanding 52.9% YoY

Price/BookValuation
2.5x8/10

Reasonable price relative to book value

Areas to Watch

AZN3 concerns · Avg: 3.3/10
P/E RatioValuation
25.6x4/10

Moderate valuation

EPS GrowthGrowth
2.5%4/10

2.5% earnings growth

Altman Z-ScoreHealth
1.482/10

Distress zone — elevated risk

ITGR4 concerns · Avg: 3.8/10
P/E RatioValuation
30.1x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
0.5%4/10

0.5% revenue growth

Altman Z-ScoreHealth
1.934/10

Grey zone — moderate risk

Profit MarginProfitability
7.6%3/10

7.6% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : AZN

The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.47 suggests the stock is reasonably priced for its growth.

Bull Case : ITGR

The strongest argument for ITGR centers on EPS Growth, Price/Book.

Bear Case : AZN

The primary concerns for AZN are P/E Ratio, EPS Growth, Altman Z-Score.

Bear Case : ITGR

The primary concerns for ITGR are P/E Ratio, Revenue Growth, Altman Z-Score.

Key Dynamics to Monitor

AZN profiles as a mature stock while ITGR is a value play — different risk/reward profiles.

ITGR carries more volatility with a beta of 0.64 — expect wider price swings.

AZN is growing revenue faster at 6.4% — sustainability is the question.

AZN generates stronger free cash flow (2.1B), providing more financial flexibility.

Bottom Line

AZN scores higher overall (60/100 vs 51/100), backed by strong 17.0% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AstraZeneca PLC

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.

Integer Holdings Corp

HEALTHCARE · MEDICAL DEVICES · USA

Integer Holdings Corporation is an outsourced manufacturer of medical devices in the United States, Puerto Rico, Costa Rica, and internationally. The company is headquartered in Plano, Texas.

Want to dig deeper into these stocks?